C. Siedel

发表

Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis.

J. Becker, E. Bröcker, P. Terheyden, 1999, The Journal of investigative dermatology.

Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma

E. Bröcker, D. Schrama, C. Vetter-Kauczok, 2006, Archives of Dermatological Research.

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

D. Schadendorf, A. Gesierich, M. Heppt, 2022, Cancers.

In situ cytokine therapy: redistribution of clonally expanded T cells

J. Becker, P. Guldberg, D. Schrama, 2001, European Journal of Immunology.

The identification of patient‐specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild‐type melanomas

B. Schilling, A. Gesierich, A. Rosenwald, 2019, Cancer.

Microvessel density and expression of vascular endothelial growth factor and its receptors in different subtypes of primary cutaneous B-cell lymphoma.

E. Bröcker, M. Goebeler, R. Houben, 2013, Acta dermato-venereologica.

Rapid differentiation of Artemia spp. Populations by thin layer isoelectric focusing

K. Simpson, C. Siedel, 1984 .

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion

G. Lenz, S. Dunn, D. Schrama, 2023, Journal of Experimental & Clinical Cancer Research.

Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils

A. Gesierich, D. Schrama, K. Wistuba-Hamprecht, 2024, Cancers.

Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density.

D. Schrama, R. Houben, C. Siedel, 2024, Molecular oncology.